Dostarlimab
An antibody that blocks the PD-1 protein on immune cells, releasing the brakes on the immune system so it can attack cancer cells more effectively. It is used to treat certain endometrial and other solid tumors.
치료 영역
Pharmacokinetics (PK)
Pharmacodynamics (PD)
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
An antibody that blocks the PD-1 protein on immune cells, releasing the brakes on the immune system so it can attack cancer cells more effectively. It is used to treat certain endometrial and other solid tumors.
Yes, Dostarlimab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4298124. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dostarlimab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dostarlimab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dostarlimab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dostarlimab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dostarlimab"></drugfyi-drug>